GlassScriptPhysician profile
Angela Hudson
NPI 1659339711
$2,885.69
in general payments reported to CMS, 2019-2025
26 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $264 · 2021: $242 · 2022: $983 · 2023: $507 · 2024: $355 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.77 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $452.93 | 2021-2025 | |
| Merz North America, INC. | $285.10 | 2022 | |
| Astellas Pharma US INC | $268.79 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $186.71 | 2019-2023 | Wallach Cryosurgical Equipment, Mara Console |
| Channel Medsystems, INC. | $173.23 | 2022 | |
| Hologic Sales and Service, LLC | $138.23 | 2022-2025 | Acessa Provu System |
| Therapeuticsmd, INC. | $92.19 | 2019-2021 | |
| Gynesonics, INC. | $91.25 | 2022 | |
| Pfizer INC. | $90.43 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $73.21 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $69.87 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $60.04 | 2020-2024 | Onzetra Xsail, Contrave |
| Viiv Healthcare Company | $49.43 | 2020 | |
| Myovant Sciences INC. | $46.94 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $44.09 | 2019-2020 | |
| Intuitive Surgical, INC. | $43.77 | 2023-2024 | |
| Evofem Biosciences, INC. | $43.42 | 2022-2025 | Solosec, Phexx, Phexxi |
| Meditrina | $35.28 | 2021-2024 | |
| Scynexis, INC. | $30.57 | 2022 | |
| Acessa Health INC. | $26.20 | 2021 | |
| Ascend Therapeutics US, LLC | $21.26 | 2023 | |
| Vertical Pharmaceuticals, LLC | $20.78 | 2019 | |
| Mission Pharmacal Company | $16.04 | 2019 | |
| Allergan, INC. | $14.80 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.